首页 | 本学科首页   官方微博 | 高级检索  
     


Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement
Authors:Selby Rita  Borah Bijan J  McDonald Heather P  Henk Henry J  Crowther Mark  Wells Philip S
Affiliation:
  • a Division of Hematology, University of Toronto, Toronto, Canada
  • b Division of Health Care Policy and Research, Mayo Clinic, Rochester, USA
  • c Bayer Inc., Toronto, Canada
  • d OptumInsight (formerly i3Innovus), Eden Prairie, USA
  • e Department of Hematology, McMaster University, Hamilton, Canada
  • f Department of Medicine, Ottawa Hospital, University of Ottawa, Canada
  • Abstract:

    Background

    The American College of Chest Physicians (ACCP) guidelines recommends thromboprophylaxis for total hip replacement (THR) and total knee replacement (TKR) patients. We examined alignment with ACCP thromboprophylaxis guidelines among THR/TKR patients, and compared symptomatic venous thromboembolism (VTE), bleeding event rates and risk factors for VTE between patients receiving ACCP-recommended thromboprophylaxis (‘ACCP’) and those who did not (‘non-ACCP’).

    Methods

    This retrospective observational study used a large US health plan claims database that was linked to an inpatient database containing detailed inpatient medication use and a database containing date-of-death information. Patients who had THR/TKR surgery between April 01, 2004 and December 31, 2006 were included. Comparisons of VTE and bleeding events between ACCP and non-ACCP patients were analyzed using chi-squared tests and multivariate logistic regression.

    Results

    Of 3,497 linked patients, 1,395 (40%) received ACCP recommended thromboprophylaxis. Of the patients who received non-ACCP recommended prophylaxis the majority (81%) received shorter than the recommended minimum 10 day prophylaxis and 118 (5.6%) of patients received no prophylaxis. Overall, non-ACCP patients were almost twice as likely to experience an incident DVT (3.76% versus 2.01%, p = 0.003) and more than eight times as likely to experience an incident PE (1.19% versus 0.14%, p = 0.001) relative to ACCP patients; there were no statistically significant difference in bleeding rates. Multivariate logistic regression indicated that the odds of a VTE event were significantly lower for ACCP patients (DVT: OR = 0.54; p = 0.006; PE: OR = 0.12; p = 0.004).

    Conclusions

    This study offers a unique perspective on ‘real-world’ thromboprophylaxis patterns and associated outcomes in THR and TKR patients in the US. It suggests that only 40% of THR/TKR patients receive ACCP-recommended thromboprophylaxis and that not receiving ACCP thromboprophylaxis is an independent risk factor for both DVT and PE.
    Keywords:ACCP, American College of Chest Physicians   CI, confidence interval   CM, clinical modification   DVT, deep vein thrombosis   GLORY, Global Orthopaedic Registry   HIPAA, Health Insurance Portability and Accountability Act   ICD, International Classification of Diseases   LMWH, low-molecular-weight heparin   OR, odds ratio   PE, pulmonary embolism   THR, total hip replacement   TKR, total knee replacement   VKA, vitamin K antagonist   VTE, venous thromboembolism
    本文献已被 ScienceDirect PubMed 等数据库收录!
    设为首页 | 免责声明 | 关于勤云 | 加入收藏

    Copyright©北京勤云科技发展有限公司  京ICP备09084417号